Ensoma's Engenious platform has been extensively validated in numerous preclinical models with a range of genome editing technologies, demonstrating robust genetic modification of bone marrow HSCs and stable long-term expression of therapeutic proteins in small and large preclinical models.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/12/21 | $70,000,000 | Series A |
5AM Ventures Alexandria Venture Investments Cormorant Asset Management F-Prime Capital Partners RIT Capital Symbiosis Takeda Ventures Viking Global Investors | undisclosed |
| 05/16/23 | $50,000,000 | Series B |
Bioluminescence Ventures Delos Capital Kite Symbiosis | undisclosed |
